Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGIK1702 adjuvant TS-1 versus cisplatin + vinorelbine in resected non-small cell lung cancer
jRCTs071180010Phase 2Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing TS-1 monotherapy with cisplatin + vinorelbine (2 arms). Primary endpoint: Two-year relapse-free survival. Started Jul 2017; status: active, not recruiting.
02
Drugs
tegafurcisplatinvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180010.